Navigation Links
Study in Cell by Magen BioSciences Co-Founder David E. Fisher,Identifies New Roles in Skin Cancer Prevention for Key Tumor,Suppressor Protein

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2007 - Magen BioSciences, Inc., a specialty dermatology company, today announced the publication of a paper in the March 9, 2007 issue of the journal Cell by its co-founder and board member, David E. Fisher, M.D., Ph.D., that identifies two new functions for an important protein, p53, in the pigmentation of skin. Fisher's study shows that in addition to its function as a tumor suppressor in other cancers in the body, p53 also plays a key role in prompting the skin to tan in response to ultraviolet light from the sun. By promoting tanning, p53 deters the development of the skin cancer melanoma, which is increasing in incidence faster than any other cancer in the world.

Fisher's research also shows that p53 causes the production of an endorphin after ultraviolet exposure, and this may modulate sensation in the skin in a manner that influences behaviors, possibly including sun-seeking behaviors.

For Magen BioSciences, the study in Cell provides important proof of concept for the company's approach to identify and develop therapeutic treatments for pigmentation disorders.

"We know that people who tan easily or have dark pigmentation are far less likely to develop melanoma," said David Fisher, with the Dana-Faber Cancer Institute. "This study suggests that p53, one of the best-known tumor-suppressor proteins in our body, goes into action when skin cells experience UV exposure, prompting the skin to tan as a defensive mechanism against DNA damage and at the same time creating endorphins that may alter sensation or even behavior."

"Dr. Fisher's discovery of this new function for a well-known protein sheds new light on the mechanism and function of tanning," said Brian Gallagher, Ph.D., Magen's president and chief executive officer. "This discovery will help Magen BioSciences identify lead compounds and develop therapeutic treatments for disfiguring dermato
'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... , July 10, 2014 Yesterday, former ... (Moberg) medical device manufacturing facility. Rep. Kennedy and ... neurological monitors facilitate cutting-edge research in neurological disease ... and mental health advocate, Garen Staglin , ... to fostering fundamental changes that will radically accelerate ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Terumo Heart, Inc. announced,today that they have ... Drug,Administration (FDA) to begin enrollment in the ... for a Bridge-to-Transplant (BTT) indication., (Logo: ... http://www.newscom.com/cgi-bin/prnh/20080303/CLM012 ), Dr. David Munjal, ...
... 29 Eisai Corporation of,North America, a wholly-owned ... the Food and Drug Administration (FDA) has accepted ... short-term (up to,eight weeks) treatment of gastroesophageal reflux ... indicated that the sNDA will receive,priority review in ...
Cached Medicine Technology:DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial 2FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents 2
(Date:7/12/2014)... 2014 Doylestown Hospital recently conducted an ... men’s health questions. Paddock tackles topics including main ... women live longer than men, and testosterone replacement therapy, ... Simple featured on Doylestown Hospital’s website, Dr. Brad ... any age. If you notice pain, bulging, or asymmetry ...
(Date:7/12/2014)... 12, 2014 Dubai is buzzing with ... is heading to the UAE. The National Basketball ... be in the UAE from 28-31 October to lead ... of diabetes awareness. The event is being organized by ... event management company based in Dubai. The announcement was ...
(Date:7/12/2014)... 12, 2014 Wright & Schulte LLC, an ... Just For Men Lawsuits (case #59776/2014), announces they have ... reports that allege the popular hair dye, Just For Men, ... their face, neck and other areas. In addition to detailing ... chemical burns , the advertisements being run by Wright & ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/11/2014)... Recently, MagicQuinceaneraDresses.com, the popular online supplier of special occasion ... Quinceanera dresses . The company’s new items are specially ... paying a large amount of money. They are all ... The company’s online shop has become a one stop ... In addition to exquisite Quinceanera dresses, it also offers ...
Breaking Medicine News(10 mins):Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
... Member Adds Operations and Marketing Expertise During a Key ... Growth Period for the Association, ... announced the appointment of Susan Trainer, chief executive,officer and founder, Trainer ... at a pivotal time for the Y, which,is in the middle ...
... While urinary stents and,catheters can be life-saving medical ... infections. With 100 million placed in patients each ... device-associated infections,annually. Nerites Corporation is testing its unique ... from a $100,000 small,business innovation research grant (SBIR) ...
... NASDAQ: CRME TSX: COM, VANCOUVER and DEERFIELD, IL, ... TSX: COM) and its co-development partner,Astellas Pharma US, Inc. ... U.S. Food and Drug Administration (FDA) that a decision ... (NDA) for KYNAPID(TM),(vernakalant hydrochloride). The FDA did not provide ...
... and Drug Administration as a palliative treatment for cancer ... sometimes used off-label for the treatment of peripheral vascular ... American Journal of Therapeutics finds that off-label use of ... adverse events and device malfunctions associated with the use ...
... COVER: "The Party,s Over" (p. 22). Editor-at-Large Evan ... in a precarious state. But the party,s,candidates can ... late to reinvent,the party,s core beliefs," writes Thomas. ... humble mission: to show, in effect, some humility. ...
... million Americans, most of them women, suffer from lupus, ... bodys own tissue. This week marks a significant step ... online publication of four new studies identifying genes involved ... K.Crow, M.D., associate chief of the division of Rheumatology ...
Cached Medicine News:Health News:Mount Diablo Region YMCA Names Local Business Leader, Susan Trainer, to Its Corporate Executive Board 2Health News:Mount Diablo Region YMCA Names Local Business Leader, Susan Trainer, to Its Corporate Executive Board 3Health News:Mount Diablo Region YMCA Names Local Business Leader, Susan Trainer, to Its Corporate Executive Board 4Health News:Cardiome And Astellas Announce Regulatory Update 2Health News:Cardiome And Astellas Announce Regulatory Update 3Health News:Cardiome And Astellas Announce Regulatory Update 4Health News:Study looks at off-label use of biliary stents 2Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 2Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 3Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 4Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 5Health News:NEJM editorial on significance and limitations of new lupus gene expression research 2Health News:NEJM editorial on significance and limitations of new lupus gene expression research 3Health News:NEJM editorial on significance and limitations of new lupus gene expression research 4
... BladderScan® BVI 6100 is a handheld, noninvasive ... is easy to operate, so any staff ... To view ultrasound images from exams and ... records and reimbursement, just log on to ...
... Contigen Bard Collagen Implant, the world's ... implant option for the treatment of Stress ... bulk to surrounding urethral tissue to aid ... with the body's own structure, Contigen Bard ...
... Prosthesis,The AMS DURA II ... of cobalt-chrome alloy strands ... gives patients what they ... positioning, cosmetic concealment and ...
... advanced three-part inflatable prosthesis consisting of a reservoir ... the scrotum and a pair of cylinders inserted ... look and performance of a natural erection. The ... AMS 700 Series now features the new Tactile ...
Medicine Products: